Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR) [clinicaltrials:NCT00370721]
Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR) [clinicaltrials:NCT00370721]
Bio2RDF identifier
NCT00370721
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00370721
identifiers.org URI
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To evaluate the effect ...... gns of active progressive PDR
brief title [clinicaltrials_vocabulary:brief-title]
Intravitreal Bevacizumab for M ...... ive Diabetic Retinopathy (PDR)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2006-08-30T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
Fibrous proliferaiton elsewhere (FPE)
Fibrous proliferation on disc (FPD)
Neovascularization elsewhere (NVE)
Neovascularization on disc (NVD)
Pan retinal photocoagulation (PRP)
Proliferative diabetic retinopathy(PDR)
Traction retinal detachment
Vitreous hemorrhage
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2008-06-25T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00370721
number of arms [clinicaltrials_vocabulary:number-of-arms]
org study id [clinicaltrials_vocabulary:org-study-id]
overall contact [clinicaltrials_vocabulary:overall-contact]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2006-03-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2008-06-01T00:00:00Z
identifier
clinicaltrials:NCT00370721
title
Intravitreal Bevacizumab for M ...... ive Diabetic Retinopathy (PDR)
@en
type
label
Intravitreal Bevacizumab for M ...... ) [clinicaltrials:NCT00370721]
@en